| HBQ Stock | | | EUR 0.20 0.05 20.00% |
CFO
Jon Odegard is Chief Financial Officer of Hofseth BioCare ASA since 2016.
| Tenure | 9 years |
| Phone | 47 73 10 22 00 |
| Web | https://www.hofsethbiocare.no |
Hofseth BioCare Management Efficiency
The company has return on total asset
(ROA) of
(0.1841) % which means that it has lost $0.1841 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.7527) %, meaning that it generated substantial loss on money invested by shareholders. Hofseth BioCare's management efficiency ratios could be used to measure how well Hofseth BioCare manages its routine affairs as well as how well it operates its assets and liabilities.
Hofseth BioCare ASA has accumulated 23.79
M in total debt with debt to equity ratio
(D/E) of 0.6, which is about average as compared to similar companies. Hofseth BioCare ASA has a current ratio of 1.76, which is within standard range for the sector. Debt can assist Hofseth BioCare until it has trouble settling it off, either with new capital or with free cash flow. So, Hofseth BioCare's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hofseth BioCare ASA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hofseth to invest in growth at high rates of return. When we think about Hofseth BioCare's use of debt, we should always consider it together with cash and equity.
Similar Executives
Hofseth BioCare ASA provides value added biomarine ingredients for human, pets, and animal feed markets in Norway and internationally. The company was founded in 2000 and is headquartered in lesund, Norway. HOFSETH BIOCARE is traded on Frankfurt Stock Exchange in Germany. Hofseth BioCare ASA (HBQ) is traded on Frankfurt Exchange in Germany and employs 63 people.
Management Performance
Hofseth BioCare ASA Leadership Team
Elected by the shareholders, the Hofseth BioCare's board of directors comprises two types of representatives: Hofseth BioCare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hofseth. The board's role is to monitor Hofseth BioCare's management team and ensure that shareholders' interests are well served. Hofseth BioCare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hofseth BioCare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Angelika Florvaag, Chief Officer | |
| Olav Flaten, Exec | |
| Tanja Schaffer, EVP GmbH | |
| Jon Odegard, Chief Financial Officer | |
| Matt Mixter, Managing Director of Hofseth, LLC | |
| Bomi Framroze, Chief Scientific Officer | |
| James Berger, Chief Officer | |
| Karl Slotsvik, Chief Officer | |
| Crawford Currie, Head Director | |
Hofseth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hofseth BioCare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Hofseth Stock
Hofseth BioCare financial ratios help investors to determine whether Hofseth Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hofseth with respect to the benefits of owning Hofseth BioCare security.